InvestSMART

Noxopharm Limited (ASX: NOX) - Announcements

Current share price for NOX : $0.081 0.008 (8.99%)+

ASX company news and announcements for Noxopharm Limited (NOX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Noxopharm Limited (NOX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Noxopharm Limited (NOX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Noxopharm Limited (NOX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$25 Idronoxil Confirmed as New Immuno-Oncology Drug 16 Apr 2019 9:54AM $0.375 $0.081 fallen by 78.40%
$25 Veyonda Chemotherapy Enhancement Program to be Expanded 10 Apr 2019 8:22AM $0.380 $0.081 fallen by 78.68%
$25 Securities to be released from Voluntary Escrow 8 Apr 2019 11:32AM $0.380 $0.081 fallen by 78.68%
$25 Updated Top 20 shareholder List 5 Apr 2019 12:19PM $0.385 $0.081 fallen by 78.96%
$25 Appendix 3B 25 Mar 2019 11:00AM $0.410 $0.081 fallen by 80.24%
$25 Section 708 Certificate 25 Mar 2019 10:58AM $0.410 $0.081 fallen by 80.24%
$25 Becoming a substantial holder 21 Mar 2019 4:42PM $0.425 $0.081 fallen by 80.94%
$25 KZA: Kazia sells stake in Noxopharm 19 Mar 2019 12:06PM $0.420 $0.081 fallen by 80.71%
$25 NOX provides update to Nyrada Note Holders 6 Mar 2019 8:33AM $0.415 $0.081 fallen by 80.48%
$25 New Corporate Presentation Released 5 Mar 2019 11:59AM $0.425 $0.081 fallen by 80.94%
$25 Noxopharm to expedite Veyonda Clinical Program 21 Feb 2019 8:46AM $0.400 $0.081 fallen by 79.75%
$25 Appendix 4D and Half Year Accounts 21 Feb 2019 8:41AM $0.400 $0.081 fallen by 79.75%
$25 Change of Director's Interest Notice - GK 14 Feb 2019 8:53AM $0.420 $0.081 fallen by 80.71%
$25 Updated Share Trading Policy 8 Feb 2019 4:29PM $0.400 $0.081 fallen by 79.75%
$25 FNN interview with Nox Chief Medical Officer on Interim Data 6 Feb 2019 11:06AM $0.450 $0.081 fallen by 82%
$25 Veyonda and Radiotherapy Delivers Clinical Benefits 6 Feb 2019 8:45AM $0.440 $0.081 fallen by 81.59%
$25 Appendix 3B 1 Feb 2019 3:06PM $0.430 $0.081 fallen by 81.16%
$25 Appendix 4C - Quarterly 29 Jan 2019 9:46AM $0.400 $0.081 fallen by 79.75%
$25 Principal Investigator Discusses LuPIN-1 Study 14 Jan 2019 10:24AM $0.400 $0.081 fallen by 79.75%
$25 Change of Director's Interest Notice - GK 21 Dec 2018 12:08PM $0.470 $0.081 fallen by 82.77%
$25 Section 708 Certificate 21 Dec 2018 12:07PM $0.470 $0.081 fallen by 82.77%
$25 Appendix 3B 21 Dec 2018 12:05PM $0.470 $0.081 fallen by 82.77%
$25 NOX Receives $3.26M Federal Govt R&D Rebate 20 Dec 2018 11:58AM $0.490 $0.081 fallen by 83.47%
$25 DARRT-1 study advancing on basis of positive clinical data 11 Dec 2018 9:06AM $0.490 $0.081 fallen by 83.47%
$25 NOX announces Positive Data from CEP-1 Study of Veyonda 29 Nov 2018 9:59AM $0.530 $0.081 fallen by 84.72%

551 - 575 of 797 results

Page 23 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.